Mycophenolic acid, an immunomodulator, has potent and broad-spectrum in vitro antiviral activity against pandemic, seasonal and avian influenza viruses affecting humans.

Autor:	To KKW; Research Centre of Infection and Immunology, The University of Hong Kong, Hong Kong Special Administrative Region, P. R. China.; Carol Yu Centre for Infection, The University of Hong Kong, Hong Kong Special Administrative Region, P. R. China.; State Key Laboratory for Emerging Infectious Diseases, The University of Hong Kong, Hong Kong Special Administrative Region, P. R. China.; Department of Microbiology, The University of Hong Kong, Hong Kong Special Administrative Region, P. R. China., Mok KY; Department of Microbiology, The University of Hong Kong, Hong Kong Special Administrative Region, P. R. China., Chan ASF; Department of Microbiology, The University of Hong Kong, Hong Kong Special Administrative Region, P. R. China., Cheung NN; Department of Microbiology, The University of Hong Kong, Hong Kong Special Administrative Region, P. R. China., Wang P; Department of Microbiology, The University of Hong Kong, Hong Kong Special Administrative Region, P. R. China., Lui YM; Department of Microbiology, The University of Hong Kong, Hong Kong Special Administrative Region, P. R. China., Chan JFW; State Key Laboratory for Emerging Infectious Diseases, The University of Hong Kong, Hong Kong Special Administrative Region, P. R. China.; Carol Yu Centre for Infection, The University of Hong Kong, Hong Kong Special Administrative Region, P. R. China.; Department of Microbiology, The University of Hong Kong, Hong Kong Special Administrative Region, P. R. China.; Research Centre of Infection and Immunology, The University of Hong Kong, Hong Kong Special Administrative Region, P. R. China., Chen H; Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Zhejiang University, 310003 Hangzhou, P. R. China.; Department of Microbiology, The University of Hong Kong, Hong Kong Special Administrative Region, P. R. China.; Research Centre of Infection and Immunology, The University of Hong Kong, Hong Kong Special Administrative Region, P. R. China.; State Key Laboratory for Emerging Infectious Diseases, The University of Hong Kong, Hong Kong Special Administrative Region, P. R. China.; Carol Yu Centre for Infection, The University of Hong Kong, Hong Kong Special Administrative Region, P. R. China., Chan KH; State Key Laboratory for Emerging Infectious Diseases, The University of Hong Kong, Hong Kong Special Administrative Region, P. R. China.; Carol Yu Centre for Infection, The University of Hong Kong, Hong Kong Special Administrative Region, P. R. China.; Research Centre of Infection and Immunology, The University of Hong Kong, Hong Kong Special Administrative Region, P. R. China.; Department of Microbiology, The University of Hong Kong, Hong Kong Special Administrative Region, P. R. China., Kao RYT; Department of Microbiology, The University of Hong Kong, Hong Kong Special Administrative Region, P. R. China.; Research Centre of Infection and Immunology, The University of Hong Kong, Hong Kong Special Administrative Region, P. R. China.; State Key Laboratory for Emerging Infectious Diseases, The University of Hong Kong, Hong Kong Special Administrative Region, P. R. China.; Carol Yu Centre for Infection, The University of Hong Kong, Hong Kong Special Administrative Region, P. R. China., Yuen KY; Research Centre of Infection and Immunology, The University of Hong Kong, Hong Kong Special Administrative Region, P. R. China.; State Key Laboratory for Emerging Infectious Diseases, The University of Hong Kong, Hong Kong Special Administrative Region, P. R. China.; Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Zhejiang University, 310003 Hangzhou, P. R. China.; Carol Yu Centre for Infection, The University of Hong Kong, Hong Kong Special Administrative Region, P. R. China.; Department of Microbiology, The University of Hong Kong, Hong Kong Special Administrative Region, P. R. China.
Jazyk:	angličtina
Zdroj:	The Journal of general virology [J Gen Virol] 2016 Aug; Vol. 97 (8), pp. 1807-1817. Date of Electronic Publication: 2016 Jun 02.
DOI:	10.1099/jgv.0.000512
Abstrakt:	Immunomodulators have been shown to improve the outcome of severe pneumonia. We have previously shown that mycophenolic acid (MPA), an immunomodulator, has antiviral activity against influenza A/WSN/1933(H1N1) using a high-throughput chemical screening assay. This study further investigated the antiviral activity and mechanism of action of MPA against contemporary clinical isolates of influenza A and B viruses. The 50 % cellular cytotoxicity (CC50) of MPA in Madin Darby canine kidney cell line was over 50 µM. MPA prevented influenza virus-induced cell death in the cell-protection assay, with significantly lower IC50 for influenza B virus B/411 than that of influenza A(H1N1)pdm09 virus H1/415 (0.208 vs 1.510 µM, P=0.0001). For H1/415, MPA interfered with the early stage of viral replication before protein synthesis. For B/411, MPA may also act at a later stage since MPA was active against B/411 even when added 12 h post-infection. Virus-yield reduction assay showed that the replication of B/411 was completely inhibited by MPA at concentrations ≥0.78 µM, while there was a dose-dependent reduction of viral titer for H1/415. The antiviral effect of MPA was completely reverted by guanosine supplementation. Plaque reduction assay showed that MPA had antiviral activity against eight different clinical isolates of A(H1N1), A(H3N2), A(H7N9) and influenza B viruses (IC50 <1 µM). In summary, MPA has broad-spectrum antiviral activity against human and avian-origin influenza viruses, in addition to its immunomodulatory activity. Together with a high chemotherapeutic index, the use of MPA as an antiviral agent should be further investigated in vivo.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu